Browse SERPINB9

Summary
SymbolSERPINB9
Nameserpin peptidase inhibitor, clade B (ovalbumin), member 9
Aliases CAP3; PI9; serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 9; CAP-3; PI-9; cytoplasmi ......
Chromosomal Location6p25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm.
Domain PF00079 Serpin (serine protease inhibitor)
Function

Granzyme B inhibitor.

> Gene Ontology
 
Biological Process GO:0001906 cell killing
GO:0001909 leukocyte mediated cytotoxicity
GO:0001910 regulation of leukocyte mediated cytotoxicity
GO:0001911 negative regulation of leukocyte mediated cytotoxicity
GO:0002228 natural killer cell mediated immunity
GO:0002443 leukocyte mediated immunity
GO:0002444 myeloid leukocyte mediated immunity
GO:0002448 mast cell mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002683 negative regulation of immune system process
GO:0002697 regulation of immune effector process
GO:0002698 negative regulation of immune effector process
GO:0002703 regulation of leukocyte mediated immunity
GO:0002704 negative regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002707 negative regulation of lymphocyte mediated immunity
GO:0002715 regulation of natural killer cell mediated immunity
GO:0002716 negative regulation of natural killer cell mediated immunity
GO:0010466 negative regulation of peptidase activity
GO:0010951 negative regulation of endopeptidase activity
GO:0031341 regulation of cell killing
GO:0031342 negative regulation of cell killing
GO:0031348 negative regulation of defense response
GO:0033668 negative regulation by symbiont of host apoptotic process
GO:0035821 modification of morphology or physiology of other organism
GO:0042267 natural killer cell mediated cytotoxicity
GO:0042269 regulation of natural killer cell mediated cytotoxicity
GO:0042270 protection from natural killer cell mediated cytotoxicity
GO:0043154 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043627 response to estrogen
GO:0044003 modification by symbiont of host morphology or physiology
GO:0044068 modulation by symbiont of host cellular process
GO:0044531 modulation of programmed cell death in other organism
GO:0044532 modulation of apoptotic process in other organism
GO:0045088 regulation of innate immune response
GO:0045824 negative regulation of innate immune response
GO:0045861 negative regulation of proteolysis
GO:0045953 negative regulation of natural killer cell mediated cytotoxicity
GO:0050777 negative regulation of immune response
GO:0051346 negative regulation of hydrolase activity
GO:0051701 interaction with host
GO:0051817 modification of morphology or physiology of other organism involved in symbiotic interaction
GO:0052040 modulation by symbiont of host programmed cell death
GO:0052041 negative regulation by symbiont of host programmed cell death
GO:0052150 modulation by symbiont of host apoptotic process
GO:0052248 modulation of programmed cell death in other organism involved in symbiotic interaction
GO:0052433 modulation by organism of apoptotic process in other organism involved in symbiotic interaction
GO:0052490 negative regulation by organism of programmed cell death in other organism involved in symbiotic interaction
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0071391 cellular response to estrogen stimulus
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2000117 negative regulation of cysteine-type endopeptidase activity
Molecular Function GO:0002020 protease binding
GO:0004857 enzyme inhibitor activity
GO:0004866 endopeptidase inhibitor activity
GO:0004867 serine-type endopeptidase inhibitor activity
GO:0004869 cysteine-type endopeptidase inhibitor activity
GO:0030414 peptidase inhibitor activity
GO:0043027 cysteine-type endopeptidase inhibitor activity involved in apoptotic process
GO:0043028 cysteine-type endopeptidase regulator activity involved in apoptotic process
GO:0061134 peptidase regulator activity
GO:0061135 endopeptidase regulator activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolSERPINB9
Nameserpin peptidase inhibitor, clade B (ovalbumin), member 9
Aliases CAP3; PI9; serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 9; CAP-3; PI-9; cytoplasmi ......
Chromosomal Location6p25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SERPINB9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between SERPINB9 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
17237823Breast CarcinomaInhibit immunity (NK cell function)In breast cancer cells, increasing concentrations of estrogen induce increasing levels of the granzyme B inhibitor, SerpinB9/proteinase inhibitor 9 (PI-9) and progressively block cell death induced by NK92 natural killer (NK) cells, but do not block killing by a second NK cell line, NKL cells. RNA interference knockdown of PI-9 abolishes estrogen's ability to block NK92 cell-induced cytotoxicity. Expressing elevated levels of estrogen receptor alpha (ERalpha) increases the induced level of PI-9, and makes tamoxifen (TAM), but not raloxifene or ICI 182,780, a potent inducer of PI-9. At elevated levels of ERalpha, induction of PI-9 by estradiol or TAM blocks killing by both NK92 and NKL cells.
16144945Stage III Cutaneous Melanoma AJCC v6; Stage IV Cutaneous Melanoma AJCC v6 and v7Resistant to immunotherapyExpression of PI-9 in metastatic melanoma cells is associated with unfavorable clinical outcome whereas MHC-1 down-regulation is not. Although it cannot be proven that PI-9 expression is directly responsible for failure of immunotherapy, these data suggest that expression of PI-9 could be an important immune escape mechanism and that modulation of this inhibitor may enhance the efficacy of immunotherapy.
Summary
SymbolSERPINB9
Nameserpin peptidase inhibitor, clade B (ovalbumin), member 9
Aliases CAP3; PI9; serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 9; CAP-3; PI-9; cytoplasmi ......
Chromosomal Location6p25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SERPINB9 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -3.08; FDR: 0.00979 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolSERPINB9
Nameserpin peptidase inhibitor, clade B (ovalbumin), member 9
Aliases CAP3; PI9; serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 9; CAP-3; PI-9; cytoplasmi ......
Chromosomal Location6p25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SERPINB9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.290.584
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3740.806
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.7710.489
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.040.918
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2840.849
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4580.823
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0780.873
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3970.793
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.5480.732
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6790.466
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4230.776
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0130.942
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SERPINB9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 382707.4-7.40.169
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1614014.3-14.30.209
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSERPINB9
Nameserpin peptidase inhibitor, clade B (ovalbumin), member 9
Aliases CAP3; PI9; serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 9; CAP-3; PI-9; cytoplasmi ......
Chromosomal Location6p25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SERPINB9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSERPINB9
Nameserpin peptidase inhibitor, clade B (ovalbumin), member 9
Aliases CAP3; PI9; serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 9; CAP-3; PI-9; cytoplasmi ......
Chromosomal Location6p25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SERPINB9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SERPINB9.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSERPINB9
Nameserpin peptidase inhibitor, clade B (ovalbumin), member 9
Aliases CAP3; PI9; serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 9; CAP-3; PI-9; cytoplasmi ......
Chromosomal Location6p25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SERPINB9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSERPINB9
Nameserpin peptidase inhibitor, clade B (ovalbumin), member 9
Aliases CAP3; PI9; serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 9; CAP-3; PI-9; cytoplasmi ......
Chromosomal Location6p25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SERPINB9 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSERPINB9
Nameserpin peptidase inhibitor, clade B (ovalbumin), member 9
Aliases CAP3; PI9; serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 9; CAP-3; PI-9; cytoplasmi ......
Chromosomal Location6p25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SERPINB9 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSERPINB9
Nameserpin peptidase inhibitor, clade B (ovalbumin), member 9
Aliases CAP3; PI9; serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 9; CAP-3; PI-9; cytoplasmi ......
Chromosomal Location6p25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SERPINB9 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting SERPINB9.
ID Name Drug Type Targets #Targets
DB00481RaloxifeneSmall MoleculeESR1, ESR2, SERPINB9, TFF14